

1 Field evaluation of a novel, rapid diagnostic assay RLDT, and molecular  
2 epidemiology of enterotoxigenic *E. coli* among Zambian children presenting with  
3 diarrhea.

4

5 **SuwilANJI Silwamba<sup>1,2</sup>, Obvious N. Chilyabanyama<sup>1</sup>, Fraser Liswaniso<sup>1</sup>, Caroline**  
6 **C Chisenga<sup>1</sup>, Roma Chilengi<sup>1</sup>, Gordon Dougan<sup>3</sup>, Geoffrey Kwenda<sup>2</sup>, Subhra**  
7 **Chakraborty<sup>4\*</sup>, Michelo Simuyandi<sup>1\*</sup>**

8

9 <sup>1</sup>Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

10 <sup>2</sup>Department of Biomedical Sciences, School of Health Sciences, University of Zambia,  
11 Lusaka, Zambia

12 <sup>3</sup>Cambridge Institute for Therapeutic Immunology and Infectious Disease, University  
13 of Cambridge, UK

14 <sup>4</sup>Department of International Health, Johns Hopkins University, USA

15

16 \*Corresponding authors:

17 Michelo Simuyandi [Michelo.Simuyandi@cidrz.org](mailto:Michelo.Simuyandi@cidrz.org)

18 Subhra Chakraborty [schakr11@jhu.edu](mailto:schakr11@jhu.edu)

19

20 Short title: Field Evaluation of a novel and rapid test for enterotoxigenic *E. coli*

21

22

23

24

25

26

27

28

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 29 **Abstract**

30

31 **Background:** Enterotoxigenic *Escherichia coli* (ETEC) is one of the top aetiologic  
32 agents of diarrhea in children under the age of 5 in low-middle income countries  
33 (LMICs). The lack of point of care diagnostic tools for routine ETEC diagnosis results  
34 in limited data regarding the actual burden and epidemiology in the endemic areas. We  
35 evaluated performance of the novel Rapid LAMP based Diagnostic Test (RLDT) for  
36 detection of ETEC in stool as a point of care diagnostic assay in a resource-limited  
37 setting.

38

39 **Methods:** We conducted a cross-sectional study of 324 randomly selected stool  
40 samples from children under 5 presenting with moderate to severe diarrhea (MSD).  
41 The samples were collected between November 2012 to September 2013 at selected  
42 health facilities in Zambia. The RLDT was evaluated by targeting three ETEC toxin  
43 genes [heat labile toxin (LT) and heat stable toxins (STh, and STp)]. Quantitative  
44 PCR was used as the “gold standard” to evaluate the diagnostic sensitivity and  
45 specificity of RLDT for detection of ETEC. We additionally described the prevalence  
46 and seasonality of ETEC.

47

48 **Results:** The study included 50.6% of participants that were female. The overall  
49 prevalence of ETEC was 19.8% by qPCR and 19.4 % by RLDT. The children between  
50 12 to 59 months had the highest prevalence of 22%. The study determined ETEC toxin  
51 distribution was LT (49%), ST (34%) and LT/ST (16%). The sensitivity and specificity  
52 of the RLDT compared to qPCR using a Ct 35 as the cutoff, were 90.7% and 97.5% for  
53 LT, 85.2% and 99.3% for STh and 100% and 99.7% for STp, respectively.

54

55 **Conclusion:** The results of this study suggest that RLDT is sufficiently sensitive  
56 and specific and easy to implement in the endemic countries. Being rapid and simple,  
57 the RLDT also presents as an attractive tool for point-of-care testing at the health  
58 facilities and laboratories in the resource-limited settings.

59

60 **Key Words:** LAMP, Enterotoxigenic *E. Coli*, qPCR, Diarrhea, Children, RLDT

61

62

### 63 **Author Summary**

64

65 ETEC is one of the top causes of diarrheal diseases in low and middle income  
66 countries. The advancement of molecular diagnosis has made it possible to accurately  
67 detect ETEC in endemic areas. However, the complexity, infrastructure and cost  
68 implication of these tests has made it a challenge to routinely incorporate them in  
69 health facilities in endemic settings. The ETEC RLDT is a simple and cost-effective  
70 molecular tool that can be used to screen for ETEC in resource limited settings. Here,  
71 we described the performance of the RLDT against a qPCR as the gold standard. Our  
72 findings showed that the ETEC RLDT performs comparable to the qPCR and would  
73 be a suitable screening tool in health facilities in resource limited settings.

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

## 90 Introduction

91  
92 Enterotoxigenic *Escherichia coli* (ETEC) is one of the top ten causes of diarrhea [1]  
93 with an estimated 75 million diarrhea episodes annually in children under the age of 5  
94 years. It is also responsible for an estimated 18,700 deaths (9,900–30,659), accounting  
95 for ~4.2% (2.2–6.8) of total diarrhea-related deaths [2]. Diarrhea is also associated with  
96 long-term consequences of poor growth and cognitive development among children  
97 [3,4]. The ETEC disease burden estimates are reportedly lower than the actual cases in  
98 endemic areas due to limited diagnostic capacity [5]. In low- and middle-income  
99 countries (LMICs), diarrhea remains a wet season disease with enteric pathogens like  
100 ETEC playing a fundamental role in warmer and wetter summer months [6,7]. It is  
101 therefore crucial to understand the seasonality of ETEC in the region to inform  
102 policymakers on prevention and control strategies.

103  
104 To accurately diagnose ETEC, one needs to first culture stool, isolate *E. coli* colonies  
105 and then test if the bacterium produces toxins (*LT*, *STh*, and *STp*) through the use of  
106 phenotypic assays such as dot blotting or through the use of conventional PCR.  
107 Quantitative PCR (qPCR) is performed with purified DNA from stool; although more  
108 sensitive; however is technology dependent and is difficult to perform without well-  
109 equipped laboratories [8]. The complex nature of the diagnosis leads to (i) long  
110 turnaround time, which in turn promotes presumptive treatment that could lead to  
111 Antimicrobial Resistance (AMR) [9,10] (ii) increase in cost and labour needed for the  
112 detection of ETEC. These are some of the reasons why ETEC is not routinely tested in  
113 resource-limited settings.

114

115

116 The complexity of these diagnostic methods results in the underestimation of the burden  
117 of ETEC because countries where the infection is endemic cannot afford the  
118 infrastructure and expertise required for this [11]. To develop an effective program for  
119 control and prevention, accurate burden data is important [12]. In resource-limited  
120 settings, there is a need for a simple, readily available method that can be used to detect  
121 ETEC in minimally equipped laboratories and health settings.

122

123 *Chakraborty et al* previously developed a simple diagnostic assay, a Rapid LAMP  
124 based Diagnostic Test (RLDT) for detection of ETEC, which is based on Loop  
125 mediated Isothermal Amplification (LAMP) [13,14]. The RLDT detects ETEC directly  
126 from stool in <1 hour. In this study, we field evaluated the RLDT in Zambia compared  
127 with qPCR, using previously collected stool samples. We also described the prevalence  
128 of ETEC infections among the Zambian children presenting with moderate to severe  
129 diarrhea (MSD) as well as asymptomatic cases, at the outpatient clinics.

130

## 131 **Materials and Methods**

132

### 133 **Study design**

134

135 This was a retrospective study using 324 randomly selected samples from 1500 stored  
136 stool samples collected at various health facilities in the Lusaka district of Zambia.  
137 These samples were collected between November 2012 to September 2013 from a  
138 previous rotavirus vaccine effectiveness study [15] as shown in Figure 1. clinical  
139 information including diarrhea severity, social demographic data were collected from  
140 study participants.

141

142 **Randomization of stool samples before selection**  
143

144 An independent statistician was tasked to randomly select 324 retrospectively  
145 collected samples. This set of samples represented stool samples with equal  
146 distribution of sex and under 5 age groups. The statistician also stratified the  
147 participant samples with a 2:1 ratio of symptomatic and asymptomatic diarrhea cases.

148 **Laboratory Assays**

149  
150 **Sample Processing Collection and Storage**  
151

152 Samples with collected clinical information of moderate to severe diarrhea and  
153 asymptomatic representation were sorted, separated and stored at -80°C before testing.

154  
155 **ETEC –RLDT Training**

156 A team from the Johns Hopkins University, United States, Baltimore travelled to  
157 Zambia to train staff at the Centre for Infectious Diseases Research in Zambia  
158 (CIDRZ) on RLDT and quantitative PCR (qPCR) assays in an effort to build  
159 laboratory capacity. The RLDT and qPCR training duration lasted 2 weeks and was  
160 followed up by evaluation of performance of the staff. The staff at CIDRZ, found that  
161 the RLDT assay is simple to use and the assay could be performed by non-skilled  
162 laboratory personnel.

163

164

165

166

167

## 168 **ETEC –RLDT Assay**

169 RLDT assays were conducted directly from the frozen stool samples using the RLDT  
170 kit as described by Chakraborty et al [13]. In short, samples were added to a sample  
171 processing tube with lysis buffer followed by heat lysis. The processed samples were  
172 then added to the ETEC RLDT lyophilized reaction tube (LRT) strips. Each strip  
173 consisted of 8 tubes, organized as two reaction tubes each for LT, STh and STp genes.  
174 One reaction tube was added as the RLDT inhibitor control [14]. The strips were run  
175 for 40 minutes in a real time fluorometer reader (Agdia Inc, IN, USA). The results were  
176 read as positive/negative by the reader.

177

## 178 **qPCR Assay**

179

180 **Nucleic Acid extraction:** About 100-150mg of bulk stool were added to SK38 bead  
181 tubes (Bertin Technologies, Montigny, France) containing lysis buffer (bioMérieux,  
182 Marcy l'Etoile, France). The stool suspension was vortexed for 5 minutes, allowed to  
183 stand at room temperature for 10 to 15 minutes, then centrifuged at 14,000 rpm for 2  
184 minutes to pellet stool material. About 200µl of the supernatant were transferred into  
185 a nuclease-free 1.5ml microcentrifuge tube for extracting nucleic acid using a  
186 QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's  
187 instructions.

188

189 **qPCR Amplification:** The 25µl reaction mixtures contained 12.5ul Quantitech SYBR  
190 Green Master mix (Qiagen, Hilden, Germany), 1uM primer mix 5ul, PCR grade water  
191 5ul (Invitrogen, USA) and 2.5ul of samples. PCR was carried out for 40 cycles of 95°C  
192 for 15s and 60°C for 1 min [16]. qPCR cycling conditions were run on the RotogeneQ  
193 platform (Qiagen, Hilden Germany). Cut-off for the determination of ETEC

194 positives was set as Ct35 as was done in previous studies [5]. Each sample was run  
195 at a minimum in duplicate, and results were averaged.

196 Chakraborty et al previously has established the limit of detection (LOD) of RLDT  
197 for ETEC genes LT, STh and STp using stool samples spiked with reference ETEC  
198 strain (PNTD-D-21-01199R1, PNTD-D-21-01198R1). The LOD was  $9 \times 10^4$  CFU/g of  
199 stool which corresponds to qPCR Ct of 28.2, 28.6 and 30.07 for LT, STh and STp  
200 respectively). Therefore, we also evaluated the performance of the RLDT using  
201 this LOD (Ct 28) as the cut off. (S2 Table).

202

## 203 **Definitions**

204 Diarrhea (Symptomatic) was defined as the primary caregiver reporting that the child  
205 had three or more loose stools within 24 hours.

206 An asymptomatic case was defined as a child presenting to a health facility with other  
207 non-diarrhea complications.

## 208 **Statistical analysis**

209

210 A minimum sample size of 324 with an assumed ETEC prevalence of 40.7% [18]  
211 produces a two-sided 95% sensitivity confidence interval with a width of 12% when  
212 the sample sensitivity is at least 85% and the two-sided 95% specificity confidence  
213 interval with a width of 5% when sample specificity is at least 0.95%. We calculated  
214 summary statistics for all baseline variables. Proportions and median (IQR) were used  
215 to express categorical and continuous variables. A Chi-square test was used to  
216 determine the association between ETEC positivity and baseline characteristics.



217 Statistical analysis significance was set at p-value <0.05 and data were analysed using  
218 Stata version 16.0 (StataCorp LLC, College Station, Texas). The correlation of ETEC  
219 monthly positivity frequencies was assessed to determine seasonality.

220 A sample was considered positive for ETEC, when at least one of the ETEC genes, LT,  
221 STh or STp was positive. To compare RLDT with qPCR, a Ct value cut off of 35 was  
222 used. Any sample with Ct value of 35 or less by qPCR was considered as true positive.  
223 To avoid incorrectly determining some samples to be false positive by RLDT, samples  
224 with Ct-values greater than 35 detectable by both qPCR and RLDT were also included  
225 as true positive. We also compared RLDT with qPCR with the Ct value cut off of 28.

226

## 227 **Ethics**

228 For this study, Ethics and regulatory approvals were sought from the University of  
229 Zambia Biomedical Research Ethics Committee (UNZABREC) reference number  
230 009- 10-18 and the National Health Regulatory Authority (NHRA). Samples were de-  
231 identified and given a unique study participant number to maintain confidentiality.

232

233

234

235

236

237

238


239

240 **Results**

241

242 **Study design is described in a flow chart (Fig 1)**

243



244

245

246 **Figure 1: Study participant flow chart**

247

248

249

250

251

252

253

254

255

256

257

258 *Social demographics and prevalence*

259

260 A total of 324 samples with a mean age of about 30months were included in the  
261 analysis, 50.9% were female, 28.4% were asymptomatic, with 3.1% of the symptomatic  
262 cases presenting with severe disease according to a modified versikari severity scoring  
263 (Denise et al unpublished) [19]. Overall, ETEC prevalence was about 19% with both  
264 the assays, RLDT and qPCR and the highest prevalence was observed in children  
265 between 12-59 months of about 22% (Table 1.)

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292 **Table 1. Baseline characteristics by qPCR/ RLDT positivity**

	Total samples tested n (%)	Positive by RLDT n (%)	p value	Positive by qPCR n (%)	p value
<b>Age</b>					
<12 months	159 (49.1)	26 (16.4)	0.41	26 (16.4)	0.44
12-23 months	37 (11.4)	9 (24.3)		8 (21.6)	
24-59 months	98 (30.2)	21 (21.4)		22 (22.4)	
missing *	30 (9.3)	7 (23.3)		8 (26.7)	
<b>Sex</b>		63		19.75	
Male	152 (46.9)	34 (22.4)	0.29	34 (22.4)	0.35
Female	165 (50.9)	29 (17.6)		30 (18.2)	
missing *	7 (2.2)	0 (0)		0 (0)	
<b>Symptomatic</b>					
No	92(28.4)	12(13)	0.07	13(14.1)	0.092
Yes	227(70.1)	51(22.5)		51(22.5)	
missing *	5(1.5)	0(0)		0(0)	
<b>Severity</b>					
Mild /Moderate	287 (88.6)	50 (17.4)	1.0 <sup>1</sup>	51 (17.8)	0.70 <sup>1</sup>
Severe	10 (3.1)	1 (10)		2 (20)	
missing *	27 (8.3)	12 (44.4)		11 (40.7)	
<b>Wash</b>					
Adequate	213 (65.7)	40 (18.8)	0.15	40 (18.8)	0.70
Inadequate	62 (19.1)	11 (17.7)		13 (21)	
missing	49 (15.1)	12 (24.5)		11 (22.4)	
<b>Total</b>	<b>324 (100)</b>	<b>63 (19.4)</b>		<b>64 (19.8)</b>	

293 NOTE: Chi square test was used to compare the association of baseline characteristics such as age, sex, Note: diarrhea severity and wash data against RLDT and qPCR ETEC  
 294 positivity. P values less than 0.05 showing a statistically significant difference. \*Statistical significance (P < 0.05).

## 295 *Performance of the RLDT against qPCR*

296 The performance of the RLDT against qPCR is shown in Table 2. The prevalence of  
297 ETEC was 19.8% by qPCR and 19.4% by RLDT. The evaluation of the LT, STh and  
298 STp toxin genes sensitivity and specificity of the RLDT using a Ct 35 value cut-off  
299 with a 95% confidence interval were, 90.7% (77.9-97.4) and 97.5% (94.8-99); (85.2%  
300 (66.3-95.8) and 99.3% (97.5-99.9); and 100% (59.0-100) and 99.7% (98.3-100))  
301 respectively. With the Ct cut off of 28, the sensitivity and specificity were higher (Table  
302 S1)

303 **Table 2. Performance of RLDT against qPCR**  
 304

<b>Ct≤35**</b>	<b>Number of samples tested</b>	<b>Samples positive by RLDT</b>	<b>Samples positive by qPCR</b>	<b>False positive</b>	<b>False negative</b>	<b>Sensitivity (95% CI)</b>	<b>Specificity(95%CI)</b>
LT	319	46	43	7	4	90.7 (77.9 -97.4)	97.5 (94.8 - 99.0)
STp	324	8	7	1	0	100 (59.0 -100.0)	99.7 (98.3-100.0)
STh	317	25	27	2	4	85.2 (66.3-95.8)	99.3 (97.5-99.9)

305

306 Note: 35\*\* a Ct value cutoff for both qPCR and the ETEC RLDT, CI = Confidence Interval

307 *Performance of RLDT against qPCR by the clinical*  
308 *representation and AUC analysis*

309 The performance of the RLDT against qPCR by the participants' clinical representation  
310 is shown in Table 3. The evaluation of symptomatic participants of the *LT*, *STh* and  
311 *STp* toxin genes sensitivity and specificity of the RLDT using the CT value cutoff of  
312 35 with a 95% confidence interval was 91.4% (76.9-99.7), and 96.8% (93.2-98.8),  
313 85.7% (63.7-97.0) and 99% (96.5-99.9) and 100% (54.1-100) and 100% (98.3-100)  
314 respectively. Similar results observed when asymptomatic cases were evaluated for  
315 sensitivity and specificity of *LT*, *STh* and *STp* (87.5% (47.4-99.7) and 98.8% (93.5-  
316 100), (83.3% (35.9-99.6) and 100% (95.8-100)) and (100% (2.5-100) and 98.9% (94-  
317 100) respectively. A comparison of the ETEC RLDT to qPCR tests for each target gene  
318 using Area Under the Curve (AUC) analysis to evaluate the performance of the two  
319 instruments. From the analysis, we found there was no significant difference between  
320 the ETEC RLDT to qPCR (Figure 2)


321 **Table 3. Performance of RLDT against qPCR by the clinical state of participants**

Ct≤35**	Clinical Status	Number of samples tested	Samples positive by RLDT	Samples positive by qPCR	False positive	False negative	Sensitivity(95%CI)	Specificity(95%CI)
LT								
	Asymptomatic	92	8	8	1	1	87.5(47.4-99.7)	98.8(93.5-100)
	Symptomatic	224	38	35	6	3	91.4(76.9-98.2)	96.8(93.2-98.8)
STp								
	Asymptomatic	92	2	1	1	0	100.0(2.5-100.0)	98.9(94.0-100.0)
	Symptomatic	227	6	6	0	0	100 (54.1-100.0)	100.0(98.3-100.0)
STh								
	Asymptomatic	91	5	6	0	1	83.3(35.9-99.6)	100(95.8-100.0)
	Symptomatic	223	20	21	2	3	85.7(63.7-97.0)	99.0 (96.5-99.9)

322 Note: 35\*\* a Ct value cutoff for both qPCR and the ETEC RLDT, CI = Confidence Interval



323



324

325

326 **Fig 2. Comparison of RLDT to qPCR tests for each gene using AUC analysis. Note:**

327 \*Statistical significance ( $p < 0.05$ )

328

329

330

331

332


333

334 *ETEC toxin gene distribution*

335 ETEC expressing only the heat Labile toxin (LT) had a frequency of 49% being the  
336 dominant expressed gene. Followed by 34% of strains expressing only the Heat stable  
337 toxin (ST) genes. The frequency of ETEC expressing the combination of both LT/ST  
338 toxins was 16% as shown in figure 3

339

340



341

342 **Fig 3. Shows the distribution of ETEC toxins**

343

344

345

346

### 347 *Seasonality*

348 We observed a seasonal trend of ETEC over 12 months with high positivity rates  
349 between December to February (warm, rainy season) and a minor peak between April  
350 and May (dry season) (Figure S1) S1 figure.

351

## 352 **Discussion**

353 This study is the first field evaluation of ETEC RLDT and establishes that it performed  
354 equally as the qPCR, as demonstrated by the specificity, sensitivity and AUC curves  
355 for each toxin gene *LT*, *STh* and *STp*. The performance of the RLDT was similar among  
356 ETEC positive diarrhea and asymptomatic cases. These findings are important as they  
357 support the use of the RLDT for screening for ETEC among children presenting with  
358 diarrhea at health facilities. In addition, its turnaround time and simplicity (not requiring  
359 skilled laboratory personnel for testing and results interpretation) makes it ideal for  
360 resource-limited settings. The RLDT could also be implemented in these countries for  
361 ETEC disease surveillance which is crucial to obtain meaningful disease burden data  
362 to inform policymakers and healthcare professionals for developing control and  
363 prevention programs. Similar studies which aimed at assessing LAMP platforms  
364 sensitivity and specificity against qPCR for the detection of *Mycoplasma pneumonia*  
365 [20] and *Leptospira spp* [21] found that both the LAMP assays had good sensitivity  
366 and specificity (99.1% and 100.0%) and (96.8% and 97.0%), respectively. These  
367 studies also concluded that the LAMP platforms are easy to use and comparable to the  
368 qPCR, as shown in this study.

369

370 We determined that across the stratified age groups, the children between 12 to 59  
371 months were at the highest risk of getting ETEC infection with prevalence of ~ 22%.  
372 The overall prevalence of ETEC under 5 years old, in this study was ~19%. The  
373 isolation rates of ETEC in our study is similar to previous studies that have reported the  
374 prevalence of ETEC in developing countries from Bangladesh, Turkey, Peru, Mexico,  
375 Egypt, Argentina, India, Nicaragua, and Tunisia which indicated a rate of 18-38% in  
376 children [22–26]. However, the ETEC prevalence in our study was lower than what  
377 was reported in a previous study (40.7%) conducted in Zambia [18] using Luminex  
378 Magpix GPP panel which uses x-TAG technology. This could be attributed to the  
379 different in testing platforms, technology and sensitivity of the assays.

380

381 The seasonal prevalence observed in our study is similar to what was reported in Kenya  
382 [27] which reported the seasonal variation of enteric bacterial pathogens among the  
383 hospitalized children with diarrhea. ETEC infections were found all year round with  
384 an increase during the warm rainy season and dry seasons. [28]. This information is  
385 critical to inform policymakers and healthcare professionals to develop control and  
386 prevention programs including when to deploy the ETEC vaccines.

387

388 We also found that in Lusaka, Zambia, among the circulating ETEC strains, the LT-  
389 ETEC strains was the highest followed by ST-ETEC and LT+ST-ETEC strains. Only  
390 6% of the ETEC strains were STp-ETEC. A similar distribution of toxin genes among  
391 ETEC strains was reported from Bolivia (LT 70%, LT+STh 23% and STh 7%) [29].  
392 Michelo et al, also reported similar results, LT+STh being the most common toxin  
393 combination and LT+STh+STp being the least common in Zambia[30]. This suggests  
394 that vaccines such as ETVAX could be effective for this population and region.

395

## 396 **Strengths**

397 This study has several strengths firstly the results of this study were obtained from  
398 samples that were collected from several health facilities across the city of Lusaka,  
399 which means that our findings can be generalized across Lusaka Province. In addition,  
400 this study included symptomatic and asymptomatic cases that were stratified by age.  
401 This sampling method accounted for some biases in the computation of the true  
402 prevalence. We conducted qPCR assays with samples run in duplicate using average  
403 CT values increasing the accuracy of the study results. This study's novelty evaluates  
404 the ETEC RLDT platform, demonstrating a successful set-up in a resource-limited  
405 setting, which is comparable to qPCR.

406

## 407 **Limitations**

408 This study has a couple of limitations which include but are not limited to (i) The cross-  
409 sectional design only provides prevalence data but does not provide incidence data,  
410 which is critical for vaccine trial design and planning control and prevention efforts.  
411 The two assays qPCR and RLDT, compared here, used different sample  
412 preparation methods. RLDT was done directly from the stool with minimum  
413 sample treatment; qPCR was done from purified DNA; Therefore, the sensitivity  
414 of these assays depends not only on the amplification technology but also on the  
415 starting material. In addition, while qPCR is quantitative, RLDT is semi-  
416 quantitative.

## 417 **Conclusion**

418 We found that the RLDT performed comparable to the qPCR assay. Additionally, the  
419 observed specificity and sensitivity are high enough to suggest that the RLDT could be  
420 used in a field setting to rapidly detect ETEC among patients presenting with diarrhea  
421 in the health facilities. This study justifies a broader application of the RLDT as a  
422 simple and rapid diagnostic test for ETEC in the endemic countries where such simple  
423 assays are critically needed. We also determined that LT-ETEC and ST-ETTEC strains  
424 were highly prevalent and ETEC positivity was highest in the warm rainy season.

425

## 426 **Author Contributions**

427

428 SS and MS drafted the original manuscript, MS worked on the Conceptualization and  
429 design of the study, SS and FL performed laboratory procedures and generated the  
430 laboratory information. OC and SC performed the statistical analysis for the study.  
431 SS, RC, SC, GD, GK, CCC and MS thoroughly reviewed and edited the article.  
432 Funding of the study MS SC GD. All the co-authors reviewed and agreed on the final  
433 submission.

434

## 435 **Acknowledgements**

436

437 We thank all clinical, data, and laboratory staff at the Centre for Infectious Disease  
438 Research in Zambia for their contributions to this work. We also acknowledge the  
439 training and material contributions from the Johns Hopkins University in Baltimore,  
440 USA.

## 441 **Funding**

442 Funding was awarded from the BactiVac global bacterial vaccinology network grant #

443 BVNCP-11

444

## 445 **References**

446

- 447 1. Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SR, et al. Estimates  
448 of the global, regional, and national morbidity, mortality, and aetiologies of  
449 diarrhoea in 195 countries: a systematic analysis for the Global Burden of  
450 Disease Study 2016. *The Lancet Infectious Diseases*. 2018;18: 1211–1228.  
451 doi:10.1016/S1473-3099(18)30362-1
- 452 2. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, et al.  
453 Morbidity and mortality due to shigella and enterotoxigenic *Escherichia coli*  
454 diarrhoea: the Global Burden of Disease Study 1990–2016. *The Lancet*  
455 *Infectious Diseases*. 2018;18: 1229–1240. doi:10.1016/S1473-3099(18)30475-4
- 456 3. Khalil I, Walker R, Porter CK, Muhib F, Chilengi R, Cravioto A, et al.  
457 Enterotoxigenic *Escherichia coli* (ETEC) vaccines: Priority activities to enable  
458 product development, licensure, and global access. *Vaccine*. 2021.  
459 doi:10.1016/j.vaccine.2021.04.018
- 460 4. Anderson JD, Bagamian KH, Muhib F, Amaya MP, Laytner LA, Wierzbza T, et  
461 al. Burden of enterotoxigenic *Escherichia coli* and shigella non-fatal diarrhoeal  
462 infections in 79 low-income and lower middle-income countries: a modelling  
463 analysis. *The Lancet Global Health*. 2019;7: e321–e330. doi:10.1016/S2214-  
464 109X(18)30483-2
- 465 5. Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of  
466 quantitative molecular diagnostic methods to identify causes of diarrhoea in  
467 children: a reanalysis of the GEMS case-control study. *The Lancet*. 2016;388:  
468 1291–1301. doi:10.1016/S0140-6736(16)31529-X
- 469 6. Levine MM, Kotloff KL, Nataro JP, Muhsen K. The Global Enteric Multicenter  
470 Study (GEMS): Impetus, rationale, and genesis. *Clinical Infectious Diseases*.  
471 2012;55. doi:10.1093/cid/cis761
- 472 7. Paredes-Paredes M, Okhuysen PC, Flores J, Mohamed JA, Padda RS, Gonzalez-  
473 Estrada A, et al. Seasonality of diarrheagenic *escherichia coli* pathotypes in the  
474 US students acquiring diarrhea in Mexico. *Journal of Travel Medicine*. 2011;18:  
475 121–125. doi:10.1111/j.1708-8305.2010.00488.x

- 476 8. Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. Recent  
477 advances in understanding enteric pathogenic *Escherichia coli*. *Clinical*  
478 *microbiology reviews*. 2013;26: 822–880. doi:10.1128/CMR.00022-13
- 479 9. Tribble DR. Resistant pathogens as causes of traveller’s diarrhea globally and  
480 impact(s) on treatment failure and recommendations. *Journal of travel medicine*.  
481 2017;24: S6–S12. doi:10.1093/jtm/taw090
- 482 10. Bokhary H, Pangesti KNA, Rashid H, Abd El Ghany M, Hill-Cawthorne GA.  
483 Travel-Related Antimicrobial Resistance: A Systematic Review. *Tropical*  
484 *Medicine and Infectious Disease*. 2021;6: 11. doi:10.3390/tropicalmed6010011
- 485 11. Lanata CF, Black RE. Estimating the true burden of an enteric pathogen:  
486 enterotoxigenic *Escherichia coli* and *Shigella* spp. *The Lancet Infectious*  
487 *diseases*. 2018;18: 1165–1166. doi:10.1016/S1473-3099(18)30546-2
- 488 12. Fleckenstein JM, Kuhlmann FM. Enterotoxigenic *Escherichia coli* Infections.  
489 *Current infectious disease reports*. 2019;21: 9. doi:10.1007/s11908-019-0665-x
- 490 13. Chakraborty. S, Connor S, Velagic M. Development of a simple, sensitive and  
491 rapid diagnostics for enterotoxigenic *E. coli* and *Shigella* spp appropriate for  
492 resource poor settings.(PNTD-D-21-01198R1). *PLoS Negl Trop Dis* In press.  
493 2022.
- 494 14. Connor S, Voeglein B, Alam M, Mukhopadhaya A, Dutta S, Wierzba. T, et al.  
495 Evaluation of a novel, simple, sensitive and rapid fieldable detection assay for  
496 ETEC and *Shigella* spp from stool samples. (PNTD-D-21-01199R1). *PLoS Negl*  
497 *Trop Dis* In press. 2022.
- 498 15. Beres LK, Tate JE, Njobvu L, Chibwe B, Rudd C, Guffey MB, et al. A  
499 Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia. *Clinical*  
500 *Infectious Diseases*. 2016;62: S175–S182. doi:10.1093/cid/civ1206
- 501 16. Bölin I, Wiklund G, Qadri F, Torres O, Bourgeois AL, Savarino S, et al.  
502 Enterotoxigenic *Escherichia coli* with STh and STp genotypes is associated with  
503 diarrhea both in children in areas of endemicity and in travelers. *Journal of*  
504 *Clinical Microbiology*. 2006;44: 3872–3877. doi:10.1128/JCM.00790-06
- 505 17. Liu J, Silapong S, Jeanwattanalert P, Lertshtakarn P, Bodhidatta L,  
506 Swierczewski B, et al. Multiplex real time PCR panels to identify fourteen  
507 colonization factors of enterotoxigenic *Escherichia coli* (ETEC). Galdiero M,  
508 editor. *PLoS ONE*. 2017;12: e0176882. doi:10.1371/journal.pone.0176882
- 509 18. Chisenga CC, Bosomprah S, Laban NM, Mwila-Kazimbaya K, Mwaba J.  
510 Aetiology of Diarrhoea in Children under Five in Zambia Detected Using  
511 Luminex xTAG Gastrointestinal Pathogen Panel. *Pediatric Infect Dis*. 2018;3: 8.  
512 doi:10.21767/2573-0282.100064
- 513 19. Denise T. St. Jean, Obvious N. Chilyabanyama, Samuel Bosomprah, Mah  
514 Asombang, Rachel M. Velu, Mwelwa Chibuye, et al. Development and  
515 validation of a diarrhoea severity scoring scale in a passive health facility-based  
516 surveillance system. (Unpublished) *PLOS One* under-review. 2021.



- 517 20. Ishiguro N, Koseki N, Kaiho M, Kikuta H, Togashi T, Watanabe T, et al.  
518 Sensitivity and Specificity of a Loop-Mediated Isothermal Amplification Assay  
519 for the Detection of Mycoplasma Pneumonia from Nasopharyngeal Swab  
520 Samples Compared with those of Real-time PCR. *Clinical laboratory*. 2015;61:  
521 603–606. doi:10.7754/clin.lab.2014.141016
- 522 21. Suwancharoen D, Sittiwicheanwong B, Wiratsudakul A. Evaluation of loop-  
523 mediated isothermal amplification method (LAMP) for pathogenic *Leptospira*  
524 spp. detection with leptospire isolation and real-time PCR. *The Journal of*  
525 *veterinary medical science*. 2016;78: 1299–1302. doi:10.1292/jvms.15-0702
- 526 22. Qadri F, Svennerholm A-M, Faruque ASG, Sack RB. Enterotoxigenic  
527 *Escherichia coli* in developing countries: epidemiology, microbiology, clinical  
528 features, treatment, and prevention. *Clinical microbiology reviews*. 2005;18:  
529 465–483. doi:10.1128/CMR.18.3.465-483.2005
- 530 23. Al-Gallas N, Bahri O, Bouratbeen A, Ben Haasen A, Ben Aissa R. Etiology of  
531 acute diarrhea in children and adults in Tunis, Tunisia, with emphasis on  
532 diarrheagenic *Escherichia coli*: prevalence, phenotyping, and molecular  
533 epidemiology. *The American journal of tropical medicine and hygiene*. 2007;77:  
534 571–582.
- 535 24. Hien BTT, Scheutz F, Cam PD, Serichantalergs O, Huong TT, Thu TM, et al.  
536 Diarrheagenic *Escherichia coli* and *Shigella* strains isolated from children in a  
537 hospital case-control study in Hanoi, Vietnam. *Journal of clinical microbiology*.  
538 2008/01/03 ed. 2008;46: 996–1004. doi:10.1128/JCM.01219-07
- 539 25. Bueris V, Sircili MP, Taddei CR, dos Santos MF, Franzolin MR, Martinez MB,  
540 et al. Detection of diarrheagenic *Escherichia coli* from children with and without  
541 diarrhea in Salvador, Bahia, Brazil. *Memorias do Instituto Oswaldo Cruz*.  
542 2007;102: 839–844. doi:10.1590/s0074-02762007005000116
- 543 26. Işeri L, Zafer Apan T, Aksoy A, Koç F, Sedef Göçmen J, Nuristani D. The  
544 prevalence of enterotoxigenic *e. Coli* isolated from the stools of children aged 0-  
545 10 years with diarrhea in mid-anatolia region, Turkey. *Brazilian journal of*  
546 *microbiology* : [publication of the Brazilian Society for Microbiology]. 2011;42:  
547 243–247. doi:10.1590/S1517-83822011000100030
- 548 27. Shah M, Kathiiko C, Wada A, Odoyo E, Bundi M, Miringu G, et al. Prevalence,  
549 seasonal variation, and antibiotic resistance pattern of enteric bacterial pathogens  
550 among hospitalized diarrheic children in suburban regions of central Kenya.  
551 *Tropical Medicine and Health*. 2016;44: 1–8. doi:10.1186/s41182-016-0038-1
- 552 28. Shah M, Kathiiko C, Wada A, Odoyo E, Bundi M, Miringu G, et al. Prevalence,  
553 seasonal variation, and antibiotic resistance pattern of enteric bacterial pathogens  
554 among hospitalized diarrheic children in suburban regions of central Kenya.  
555 *Tropical Medicine and Health*. 2016;44: 1–8. doi:10.1186/s41182-016-0038-1
- 556 29. Rodas C, Mamani R, Blanco J, Blanco JE, Wiklund G, Svennerholm AM, et al.  
557 Enterotoxins, colonization factors, serotypes and antimicrobial resistance of  
558 enterotoxigenic *Escherichia coli* (ETEC) strains isolated from hospitalized

559 children with diarrhea in Bolivia. *Brazilian Journal of Infectious Diseases*.  
560 2011;15: 132–137. doi:10.1016/S1413-8670(11)70158-1

561 30. Simuyandi M, Chilengi R, B Connor S, B. Voeglein J, M. Laban N, Mwila-  
562 Kazimbaya K, et al. Enterotoxigenic *Escherichia Coli* Toxins and Colonization  
563 Factors Among Zambian Children Presenting with Moderate to Severe Diarrhea  
564 to Selected Health Facilities. *Arch Microbiol Immunology*. 2019;03.  
565 doi:10.26502/ami.93650039

566

567

568

569

570

571 **Data sharing statement**

572

573 The underlying data set cannot be made publicly available because it contains human  
574 research participant data; however, it can be made available to any interested  
575 researchers upon request. The Centre for Infectious Disease Research in Zambia  
576 (CIDRZ) Ethics and Compliance Committee is responsible for approving such requests.  
577 To request data access, one must write to the Secretary to the Committee (via.  
578 [info@cidrz.org](mailto:info@cidrz.org)) mentioning the intended use for the data, contact information, a  
579 research project title, and a description of the analysis being proposed as well as the  
580 format it is expected. The requested data should only be used for purposes related to  
581 the original research or study. The CIDRZ Ethics and Compliance Committee will  
582 normally review all data requests within 48–72 hours (Monday-Friday), and provide  
583 notification if access has been granted or additional project information is needed.

584

585

586

587

588